Inhibition of CD4 expression by antisense oligonucleotides in PMA-treated lymphocytes

Antisense and Nucleic Acid Drug Development

Volumn 12, Issue 6, 2002, Pages 399-410

  Rabanal, Manuel ^a   Franch, Àngels ^a   Noé, Véronique ^a   Ciudad, Carlos J ^a   Castell, Margarida ^a   Castellote, Cristina ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE CD4 1; ANTISENSE OLIGONUCLEOTIDE CD4 2; ANTISENSE OLIGONUCLEOTIDE CD4 3; ANTISENSE OLIGONUCLEOTIDE CD4 4; CD4 ANTIGEN; LIPOSOME; MESSENGER RNA; N [1 (2,3 DIOLEOYLOXY)] N,N,N TRIMETHYLAMMONIUM PROPANE METHYL SULFATE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHORBOL 12 ACETATE 13 MYRISTATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CELL FUNCTION; CELL SURFACE; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HELPER CELL; IMMUNOFLUORESCENCE; IMMUNOPHARMACOLOGY; IN VITRO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN LYMPHOCYTE;

ANIMALIA;

EID: 0036978183     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729002321082474     Document Type: Article

References (33)

1. ACRES, R.B., CONLON, P.J., MOCHIZUKI, D.Y., and GALLIS, B. (1986). Rapid phosphorylation and modulation of the T4 antigen on cloned helper T cells induced by phorbol myristate acetate or antigen. J. Biol. Chem. 261, 16210-16214.
2. ADLER, S.H., and TURKA, L.A. (2002). Immunotherapy as a means to induce transplantation tolerance. Curr. Opin. Immunol. 14, 660-665.
3. BAKER, B.F., CONDON, T.P., KOLLER, E., McKAY, R.A., SIWKOWSKI, A.M., VICKER, T.A., and MONIA, B.P. (2001). Discovery and analysis of antisense oligonucleotide activity in cell culture. Methods 23, 191-198.
4. BENETT, C.F., CHIANG, M.Y., CHAN, H., SHOMAKER, J.E., and MIRABELLI, C.K. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41, 1023-1033.
5. CAMMAROTA, G., SHELIE, A., TAKACS, B., DORAN, D.M., KNORR, R., BANNWARTH, W., GUARDIOLA, J., and SINIGAGLIA, F. (1992). Identification of a CD4 binding site on the β2 domain of HLA-DR molecules. Nature 356, 799-801.
6. CAPACCIOLI, S., DI PASQUALE, G., MINI, E., MAZZEI, T., and QUATTRONE, A. (1993). Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem. Biophys. Res. Commun. 197, 818-825.
7. CHAMBERS, C.A. (2001). The expanding world of co-stimulation: The two-signal model revised. Trends Immunol. 22, 217-223.
8. CLARK, S.J., JEFFERIES, W.A., BARCLAY, W., GAGNON, J., and WILLIAMS, A.K. (1987). Peptide and nucleotide sequences of rat CD4 (W3/25) antigen: Evidence for derivation from a structure with four immunoglobulin-related domains. Proc. Natl. Acad. Sci. USA 84, 1649-1653.
9. DARZYNKIEWICZ, Z., LI, X., and GONG, J. (1994). Assays of cell viability: Discrimination of cells dying by apoptosis. Methods Cell Biol. 41, 15-38.
10. DAVIS, M.M., BONIFACE, J.J., REICH, Z., LYONS, D., HAMPL, J., ARDEN, B., and CHIEN, Y. (1998). Ligand recognition by alpha-beta T cell receptors. Annu. Rev. Immunol. 16, 523-544.
11. GAO, W.Y., HAN, F.S., STORM, C., EGAN, W., and CHENG, Y.C. (1992). Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Mol. Pharmacol. 41, 223-229.
12. HARTMANN, G., KRUG, A., BIDLINGMAIER, M., HACKER, U., EIGLER, A., ALBRECHT, R., STRASBURGER, C.J., and ENDRES, S. (1998). Spontaneous and cationic-lipid mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J. Pharmacol. Exp. Ther. 285, 920-928.
13. HOXIE, J.A., MATTHEWS, D.M., CALLAHAN, K.J., CASSEL, D.L., and COOPER, D.A. (1986). Transient modulation and internalization of T4 antigen induced by phorbol esters. J. Immunol. 137, 1194-1201.
14. ISAACS, J.D., MORGAN, A.W., and STRAND, V. (1999). Combination biologic therapy. Clin. Exp. Rheumatol. 17(Suppl. 18), S121-S124.
15. JANEWAY, C.A.J. (1989). The role of CD4 in T-cell activation: Accessory molecule or coreceptor? Immunol. Today 10, 234-238.
16. KRUMMEL, M.F., and DAVIS, M.M. (2002). Dynamics of the immunological synapse: Finding, establishing and solidifying a connection. Curr. Opin. Immunol. 14, 66-74.
17. MARTIN, M.M., and LINDQVIST, L. (1975). The pH dependence of fluorescein fluorescence. J. Luminesc. 10, 381-390.
18. MAURI, C., CHU, C.C.Q., WOODROW, D., MORI, L., and LONDEI, M. (1997). Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody. J. Immunol. 159, 5032-5041.
19. MOLLER, B.K., ANDRESEN, B.S., CRISTENSEN, E.I., and PETERSEN, C.M. (1990). Surface membrane CD4 turnover in phorbol ester stimulated T-lymphocytes. FEBS Lett. 276, 59-62.
20. MORRISON, W.J., OFFNER, H., and VANDENBARK, A.A. (1994). Enhanced T-helper cell function following CD4 modulation. Cell. Immunol. 153, 392-400.
21. NEPOM, G.T. (2002). Therapy of autoimmune diseases: Clinical trials and new biologics. Curr. Opin. Immunol. 14(6), 812-815.
22. PARKS, D.R., BRYAN, V.M., OI, V.T., and HERZENBERG, L.A. (1979). Antigen-specific identification and cloning of hybridomas with a fluorescence-activated cell sorter (FACS). Proc. Natl. Acad. Sci. USA 76, 1962-1966.
23. PELEGRÍ, C., MORANTE, M.P., I CASTELLOTE, C., CASTELL, M., and FRANCH, A. (1995). Administration of a nondepleting anti-CD4 monoclonal antibody (W3/25) prevents adjuvant arthritis, even upon rechallenge: Parallel administration of a depleting anti-CD8 monoclonal antibody (OX8) does not modify the effect of W3/25. Cell. Immunol. 165, 177-182.
24. PELEGRÍ, C., MORANTE, M.P., CASTELLOTE, C., FRANCH, A., and CASTELL, M. (1996). Treatment with an anti-CD4 monoclonal antibody strongly ameliorates established rat adjuvant arthritis. Clin. Exp. Immunol. 103, 273-278.
25. PÉREZ, J.R., LI, Y., STEIN, C.A., MAJUNDER, S., VAN OORSCHOT, A., and NARAYANAN, R. (1994). Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligonucleotides. Proc. Natl. Acad. Sci. USA 91, 5957-5961.
26. PEYMAN, A., and UHLMANN, E. (1996). Minimally modified oligonucleotides - Combination of end-capping and pyrimidine-protection. Biol. Chem. Hoppe-Seyler 377, 67-70.
27. PICHON, C., MONSIGNY, M., and ROCHE, A.C. (1999). Intracellular localization of oligonucleotides: Influence of fixative protocols. Antisense Nucleic Acid Drug Dev. 9, 89-93.
28. RODRÍGUEZ, M., NOÉ, V., ALEMANY, C., MIRALLES, A., BEMI, V., CARAGOL, I., and CIUDAD, C.J. (1999). Effect of anti-sense oligonucleotides directed toward dihydrofolate reductase RNA in mammalian cultured cells. Int. J. Cancer. 81, 785-792.
29. TARNER, I.H., and FATHMAN, C.G. (2001). Gene therapy in autoimmune disease. Curr. Opin. Immunol. 13, 676-682.
30. TAYLOR, M.F., PAULASKIS, J.D., WELLER, D.D., and KOBZIK, L. (1996). In vitro efficacy of morpholino-modified antisense oligomers directed tumor necrosis factor-α mRNA. J. Biol. Chem. 271, 17445-17452.
31. WHITE, R.A.H., MASON, D.W., WILLIAMS, A.F., GALFRE, G., and MILSTEIN, C. (1978). T-lymphocyte heterogeneity in the rat: Separation of functional subpopulations using a monoclonal antibody. J. Exp. Med. 148, 664-673.
32. YAKUBOV, L., KHALED, Z., ZHANG, L.M., TRUNEH, A., VLASSOV, V., and STEIN, C.A. (1993). Oligodeoxynucleotides interact with recombinant CD4 at multiple sites. J. Biol. Chem. 268, 18818-18823.
33. ZELPHATI, O., and SZOKA, F.C. (1996). Intracellular distribution and mechanisms of delivery of oligonucleotides mediated by cationic lipids. Pharmaceutical Res 13, 1367-1372.